Dinutuximab
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
- Dinutuximab
- Pharmacist Assessment Report
- Dinutuximab: From Neuroblastoma to Vertebral Anomalies and Variable Endocrine and T-cell Dysfunction
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Cytotoxicity
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Dinutuximab: From Neuroblastoma to Vertebral Anomalies and Variable Endocrine and T-cell Dysfunction
One-Sentence Summary
Dinutuximab is an anti-GD2 monoclonal antibody, originally used to treat neuroblastoma. The TxGNN model predicts it may be effective for vertebral anomalies and variable endocrine and T-cell dysfunction, a rare developmental and immunodeficiency syndrome. There are currently 0 clinical trials and 0 publications supporting this specific prediction. The score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Neuroblastoma |
| Predicted New Indication | Vertebral anomalies and variable endocrine and T-cell dysfunction |
| TxGNN Prediction Score | 0.9942 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the compiled drug record. Dinutuximab is known to be a monoclonal antibody against GD2, a ganglioside found on the surface of neuroblastoma cells. Its efficacy in neuroblastoma rests on targeting GD2-expressing tumour cells.
No mechanistic link is apparent for this prediction. The predicted condition is a rare developmental and immunodeficiency syndrome with no known GD2-driven disease process. The high TxGNN score (0.9942) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. No trials or publications support it. It should be treated as a hypothesis-generating signal, not as evidence of benefit.
The other two candidates, retroperitoneal neoplasm and BCR-ABL1-positive chronic myelogenous leukaemia, have no supporting trials or publications. The leukaemia prediction has no credible mechanistic rationale, because the disease is driven by the BCR-ABL1 fusion kinase rather than GD2.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02483076 | UNITUXIN | Not specified | Not specified in the compiled data (neuroblastoma is the original indication) |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy (anti-GD2 monoclonal antibody), not a conventional cytotoxic chemotherapy |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert and local institutional policy for handling of antineoplastic agents |
Safety Considerations
Drug Interactions (100 interactions recorded; the main ones from the available list are shown below)
- Major interactions:
- Corticosteroids: hydrocortisone, triamcinolone, dexamethasone, beclomethasone dipropionate, betamethasone, budesonide, prednisolone, prednisone
- Deferiprone
- Samarium (153Sm) lexidronam
- Moderate interactions:
- Metronidazole, tinidazole, secnidazole, benznidazole
- Rosuvastatin, simvastatin
- Chloroquine, hydroxychloroquine
- Disulfiram
- Strontium chloride Sr-89
The many major corticosteroid interactions deserve particular attention if dinutuximab were ever combined with these agents in a new patient population.
For warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score but no clinical trials, no literature, and no plausible GD2-related mechanism for this rare syndrome. Evidence is at the lowest level (L5), so there is no basis for further investment in this indication.
To proceed, the following is needed:
- A credible biological rationale linking GD2 targeting to the predicted condition
- Any preclinical or clinical data specific to this condition
- The Health Canada package insert warnings and contraindications, which are needed before any safety screening
- Detailed mechanism-of-action data from DrugBank
- Consideration of ganglioneuroblastoma as a more plausible lead, which would first require confirming the design and subgroup data of the neuroblastoma-family study (COG ANBL1221)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.